Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Feb 5.
Published in final edited form as: Nat Protoc. 2011 Jul 7;6(8):1085–1104. doi: 10.1038/nprot.2011.346

Knock-out and pull-out recombineering protocols for naturally transformable Burkholderia thailandensis and Burkholderia pseudomallei

Yun Kang 2, Michael H Norris 2, Bruce A Wilcox 3, Apichai Tuanyok 4, Paul S Keim 4,5, Tung T Hoang 1,2,*
PMCID: PMC3564556  NIHMSID: NIHMS431679  PMID: 21738123

Summary

Phage λ Red proteins are powerful tools for pulling- and knocking-out chromosomal fragments but have been limited to the γ-proteobacteria. Procedures are described here to easily knock-out (KO) and pull-out (PO) chromosomal DNA fragments from naturally transformable Burkholderia thailandensis and Burkholderia pseudomallei. This system takes advantage of published compliant counter-selectable and selectable markers (sacB, pheS, gat, and the arabinose utilization operon) and λ Red mutant proteins. pheS-gat (KO) or oriT-ColE1ori-gat-ori1600-rep (PO) PCR fragments are generated with flanking 40–45 bp homologies to targeted regions incorporated on PCR primers. One-step recombination is achieved by incubating the PCR product with cells expressing λ Red proteins and subsequent selection on glyphosate-containing medium. This procedure takes approximately 10 days and is advantageous over previously published protocols: i) smaller PCR products reduce primer numbers and amplification steps, ii) PO fragments for downstream manipulation in E. coli, and iii) chromosomal KO increases flexibility for downstream processing.

INTRODUCTION

The ability to manipulate the bacterial chromosome for molecular genetics, pathogenesis, and bacteria-host interaction studies is crucial for the discovery of novel vaccine, therapeutic, and diagnostic targets. The Gam, Exo, and Beta proteins of coliphage λ aid in the RecA-independent homologous recombination process to pull-out (PO) or knock-out (KO) regions from bacterial chromosomes1. These λ Red proteins facilitate high frequency recombination between the chromosome and small homologous sequences (~40–45 bp) flanking a selectable marker. However, PO and KO manipulation of the bacterial genome using the λ Red system has been limited to the γ-proteobacteria class25. Therefore, protocols to expand the use of λ Red recombineering beyond the γ-proteobacteria are needed, particularly for two closely related naturally transformable β-proteobacterial species Burkholderia thailandensis and Burkholderia pseudomallei.

B. thailandensis is a relatively non-pathogenic bacterium often used as a model microbe to study various aspects of the potential bioterrorism agent B. pseudomallei. B. pseudomallei is the etiological agent of melioidosis, a globally emerging and often fatal infectious disease6. Work by Thongdee et al.7 has demonstrated the KO of chromosomal fragments in both naturally transformable Burkholderia species using PCR fragments generated by three fragment overlap-extension PCR. The requirement for large homologous regions (800–1000 bp) and overlapping PCR can be hampered by the size and G+C content of the target DNA. In addition, screening for KOs with primers annealing to chromosomal regions outside of the 800–1000 bp of homology can be difficult due to increased amplicon size. Because of these limitations and the lack of PO protocols, we developed protocols to extend the λ Red recombineering potential in these two species. Here, we present protocols for λ Red recombineering to capture or delete, for example, large chromosomal DNA fragments from two β-proteobacteria species, B. thailandensis and B. pseudomallei.

Advantages and potential beyond the presented protocols

There are general advantages to this one-step λ Red facilitated PO/KO recombineering protocol: i) arabinose selection (araBCDEFGHI) of pKaKa2 (Fig. 1) works in ara- E. coli and B. pseudomallei (Table 1); ii) the pheS-gat FRT-cassette, containing both selectable and counter-selectable markers, is small and can be used throughout the Burkholderia genus8,9; iii) the use of these non-antibiotic (counter)selectable markers is in compliance with CDC/NIH guidelines and they provide efficient (counter)selection with high frequencies of positive recombinants; iv) there is no requirement to maintain and/or cure a replicating plasmid encoding Flp for FRT-cassette excision and the flp-containing PCR product incubation protocol is simple and saves time; v) it is more cost effective since multiple fragment overlap-extension PCR7 (can be difficult for larger DNA fragments with high G+C content) is not required in this protocol, thus reducing the number of oligos used; vi) recombination aided by λ Red proteins effectively reduces the length of homologous regions required (40–45 bp), whereas no recombination occurs without the induction of λ Red proteins (i.e. DNA incubation alone); vii) possible secondary chromosomal mutation(s) in the 800–1000 bp of homology resulting from overlap-extension PCR are avoided in λ Red recombineering which only requires 40–45 bp of homology.

Figure 1.

Figure 1

Genetic constructs for KO and PO recombineering in B. thailandensis and B. pseudomallei. (a) Plasmid pKaKa1 contains λ Red genes (gam-bet-exo)17 driven by the arabinose inducible promoter (ParaB). (b) Plasmid pKaKa2 is maintained in ara- E. coli and B. pseudomallei strains by the B. thailandensis arabinose-utilization operon and growth on arabinose minimal medium, where λ Red genes are driven by the rhamnose inducible promoter. (c) Broad-host-range (bhr) replicating plasmid used for PO recombineering (in vivo cloning). Target-PO1 and Target-PO2 indicate primers (blue arrows), with 40–45 bp homology to the targeted chromosomal region, used to obtain PCR products (oriT-ColE1ori-gat-ori1600-rep) to PO targeted sequences. (d) The pheS -gat and sacB-gat FRT-cassettes used for KO recombineering experiments. Target-KO1 and Taget-KO2 indicate primers (blue arrows), with 40–45 bp homology to chromosomal regions, used to amplify this cassette in KO experiments. Abbreviations: araCEc of pKaKa1, activator of the arabinose inducible promoter (ParaB) from E. coli; araBCDEFGHI of pKaKa2, B. thailandensis arabinose utilization operon10; bla, encodes β-lactamase; ColE1-ori, ColE1 origin of replication obtained from high copy number pUC vectors25; FRT, yeast 2 μm plasmid Flp recombination target; gat, glyphosate (GS) acetyl transferase for GS resistance9; Kmr, kanamycin resistance encoded by nptII26; lacZα, encodes LacZ alpha peptide; mob-oriT; RP4-dependent conjugal origin of transfer of B. bronchiseptica cryptic plasmid pBBR116; ori1600-rep, Pseudomonas and Burkholderia bhr origin of replication27; ori-rep; bhr replicon of B. bronchiseptica pBBR1 plasmid16; oriT, plasmid RP4 origin of transfer for conjugation; ParaB, arabinose inducible promoter3; Plac, E. coli lactose operon promoter; PrhaBAD, rhamnose inducible promoter28; PS12 and PCS12, constitutive promoters of B. pseudomallei and B. cenocepacia rpsL gene29; pheS, engineered gene encoding a mutant version of α-subunit of phenylalanyl tRNA synthase8; rhaR and rhaS, regulators of the rhamnose inducible promoter28; sacB, encoding for a modified levansucrase counter-selectable marker14.

TABLE 1.

Strains and plasmids utilized in this study.

Strains/plasmids Lab IDa Accession Numberb Relevant Features and Use Reference
E. coli
 EPMax10B E1231 - F-λ-mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 ΔlacX74 deoR recA1 endA1 araD139 Δ(ara, leu)7697 galU galK rpsL nupG BioRad
 EPMax10B-lacIq/pir/leu+ E1889 - F-λ-mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 ΔlacX74 deoR recA1 galU galK rpsL nupG lacIq-FRT8 pir-FRT4 -c
 EPMax10B-pir116asd/ mob-Kmrtrp::Gmr E1354 - Gmr, Kmr; F-λ-mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 ΔlacX74 deoR recA1 endA1 araD139 Δ(ara, leu)7697 galU galK rpsL nupG Tn-pir116-FRT2 Δasd::wFRT Δtrp::Gmr-FRT5 mob[recA::RP4-2 Tc::Mu-Kmr] -c
 MC4100-Δasd::FRT/ mob::mFRT E1299 - F (argF lac) U169 araD139 rpsL150 relA1 thiA ptsF25 deoC1 flbB5301 rbsR Δasd::FRT recA:RP4-2Tc::Mu

B. pseudomallei d
 1026b B004 - Wildtype strain; clinical melioidosis isolate 22
 1026b-Δmba::pheS-gat B023 - GSr; 1026b with pheS-gat-FRT fragment replacing the mba cluster This study
 1026b-Δmba::FRT B025 - 1026b with FRT-sequence inserted into the mba cluster This study
 1026b-Δmba B027 - 1026b with mba cluster deleted This study
 Bp0085 B040 - Wildtype strain; clinical strain from a sepsis case (fatal) in Thailand, 2006 This study
 Bp0085-Δasd::pheS-gat B079 - GSr; Bp0085 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp0091 B042 - Wildtype strain; clinical strain from a sepsis case (fatal) in Thailand, 2006 This study
 Bp0091-Δasd::pheS-gat B080 - GSr; Bp0091 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp0094 B044 - Wildtype strain; clinical strain from a sepsis case (fatal) in Thailand, 2006 This study
 Bp0094-Δasd::pheS-gat B081 - GSr; Bp0094 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp4001e B054 - Wildtype strain; environmental isolate from soil in Australia, 1997 This study
 Bp4001-Δasd::pheS-gat B082 - GSr; Bp4001 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp4003e B058 - Wildtype strain; clinical strain from a sepsis case (fatal) in Australia, 1999 This study
 Bp4003-Δasd::pheS-gat B083 - GSr; Bp4003 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp4122 B064 - Wildtype strain; environmental isolate from soil in Australia, 2006 This study
 Bp4122-Δasd::pheS-gat B084 - GSr; Bp4122 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp4141e B066 - Wildtype strain; clinical isolate from a chronic case (survived) in Australia, 1991 This study
 Bp4141-Δasd::pheS-gat B085 - GSr; Bp4141 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp4144 B068 - Wildtype strain; clinical isolate from a chronic case (survived) in Australia, 1995 This study
 Bp4144-Δasd::pheS-gat B086 - GSr; Bp4144 with pheS-gat-FRT fragment replacing the asd gene This study
 Bp6340e B078 - Wildtype strain; clinical isolate from a chronic case (survived) in Australia, 2003 This study
 Bp6340-Δasd::pheS-gat B087 - GSr; Bp6340 with pheS-gat-FRT fragment replacing the asd gene This study

B. thailandensis
 E264 E1298 - Prototroph; environmental isolate 23

Plasmids
 pAM3G E1947 GU074522 GSr; broad-host-range cloning vector based on GS resistance This study
 pwFRT-pheS-gat E2336 GU074523 GSr, Apr; pheS-gat fragment flanked by wildtype FRTs This study
 pwFRT-gat-sacB E2456 GU450326 GSr, Apr; sacB-gat fragment flanked by wildtype FRTs This study
 pKaKa1 E2273 GU074524 Kmr; broad-host-range λ-red helper plasmid based on Km resistance This study
 pKaKa2 E2334 GU074525 broad-host-range helper plasmid for λ-red recombineering This study
 pCD13SK-Flp-oriT-asdEc E1827 EU626138 Suicidal plasmid containing Flp 24
a

Please use Lab ID when requesting E. coli strains and plasmids.

b

Genbank accession number.

c

Details on the construction of these strains/plasmids will be published elsewhere.

d

Acquisition, possession, and manipulation of these strains in the United States are limited to FBI screened and cleared personnel and experiments must be perfomred in a CDC/USDA approved and registered BSL-3 select agent laboratory.

e

Multiple-contig shotgun assemblies from these strains are available upon request.

There are other advantages specific to λ Red mediated in vivo cloning (Fig. 2). PCR amplification of the insert, which can generate mutations in the fragment to be cloned, is not required. In addition, large PCR products can be difficult to amplify, especially from the high G+C DNA of Burkholderia species. Using this protocol to PO large chromosomal fragments from Burkholderia spp. is much faster than, for example, recA-mediated recombination of a suicidal plasmid at the region of interest followed by restriction fragmentation, ligation, and cloning in E. coli10. The cloned junctions can be precise depending on primer design, and unique restriction sites can be added to the middle of the Target-PO oligos for easy downstream manipulation of in vivo cloned fragments. It can be envisioned that the PO protocol could generate clones of much larger or smaller fragments than the 11.6 to 31.5 kb fragments exemplified in this protocol.

Figure 2.

Figure 2

Overview of an example of PO recombineering in B. pseudomallei. The 31.5 kb mba-cluster was pulled-out of the B. pseudomallei chromosome, using a PCR amplified fragment of the pAM3G backbone (Fig. 1c), with correctly oriented 40–45 bp homologous sequences toward the mbaF and mbaS genes. Positive clones can be immediately obtained in one step via glyphosate resistance selection. The pAM3G-mba bhr replicating plasmid could be screened (with the primers indicated by arrows) and isolated from glyphosate resistant B. pseudomallei colonies and transformed into E. coli for further characterization. Red crosses indicate λ-red mediated homologous recombination.

Furthermore, the KO protocol could be extended to include other downstream applications. Insertional mutants may be created with the pheS-gat FRT-cassette such that the counter-selectable markers could be used to counterselect and generate reporter-gene fusions, in-frame non-polar deletions, and chromosomal point mutations in these β-proteobacteria, B. thailandensis and B. pseudomallei, as previously described for other γ-proteobacteria species1. Overall, the ability to perform these types of genetic manipulations in these species using λ Red recombineering significantly simplifies and reduces experimental labor, allowing high-throughput targeted chromosomal manupulation. For example, our lab has utilized this to knock-out over 200 targeted and confirmed mutations in one month by two graduate students.

Limitations of the present protocol

The limitations of the current protocol are that: i) there is a requirement for minimal media (typically 1× M9 glucose) supplemented with GS or cPhe during gat or pheS selection; ii) when introduced into E. coli at high copy number, certain PO gene products may be toxic to the cell, potentially limiting the nature of downstream applications; and iii) this protocol has been performed successfully in only the naturally transformable strains of B. thailandensis and B. pseudomallei (approximately 50% of the strains tested in this study). we have not been able to extend its use to the non-naturally transformable Burkholderia species (e.g. B. pseudomallei strain K96243 and B. mallei strain ATCC23344) due to potentially inefficient electrotransformation and/or restriction barriers against double-stranded DNA. Various published electroporation methods1113 were tested in non-naturally transformable strains (e.g. B. pseudomallei K96243 and B. mallei ATCC23344) but no colonies or recombinants were obtained. In these non-naturally transformable species and strains, mutation could be created with other established mutagenesis precedures, as previously described8,9,12,14. However, lambda-red recombineering is very broad-host-range, and we strongly believe that these tools will work in many other natural transformable strains. For example, we have extended the use of this technology successfully in nine other naturally transformable B. pseudomallei environmental and clinical strains (Table 1).

EXPERIMENTAL DESIGN

Genetic Constructs for Recombineering

This protocol takes advantage of our recently published pheS counter-selectable and gat selectable markers8,9, along with the arabinose utilization operon (araBCDEFGHI)10 and the more established sacB counter-selectable marker14. Two new broad-host-range (bhr) replicating plasmids containing λ Red genes (gam, bet, and exo) that are inducible with arabinose and rhamnose, pKaKa1 and pKaKa2, respectively, were engineered for this protocol (Fig. 1a and 1b). pKaKa1 is typically used for B. thailandensis, using the kanamycin resistance selectable marker and the pheS gene as a counter-selectable marker in the presence of chlorinated phenylalanine (cPhe) as described previously8. Since kanamycin resistance has limited use in wildtype B. pseudomallei strains15, the alternative B. thailandensis arabinose utilization operon (araBCDEFGHI)10 was used as a metabolic marker for selection of pKaKa2 in B. pseudomallei, while the sacB gene was chosen for counter-selection using sucrose. The pKaKa1 and pKaKa2 plasmids contain the Bordetella bronchiseptica bhr origin for replication in Gram-negative bacteria16. These plasmids can be electrotransformed into B. thailandensis and B. pseudomallei or conjugated from RP4-harboring E. coli (e.g. E1299, Table 1), where they can eventually be cured using cPhe or sucrose after recombineering. The λ Red proteins Gam, Redβ, and Redα (encoded by gam, bet, and exo genes) are based on optimized expression of Gam and mutated versions of Redβ and Redα17. Upon induction of the λ Red proteins, linear PCR products are naturally transformed into B. thailandensis or B. pseudomallei to generate POs or KOs. The relevant strains, plasmids, and oligonucleotides used in this protocol are shown in Tables 1 and 2.

TABLE 2.

Oligonucleotides utilized in this study.

Number/Name Sequencea
#1178; araA-PO1 graphic file with name nihms431679t1.jpg
#1179; araI-PO2 graphic file with name nihms431679t2.jpg
#1227; araA-PO3 5′-CGCGCGGGAGATCTAC-3′
#1228; araI-PO4 5′-GAAGCGGGCTGCGCGAA-3′
#271; ori1600-rep-internal 5′-GGAAGATTTCAGATGCTGAG-3′
#1161; araI-rev 5′-TTCGTGTTCGGGATGAAG-3′
#1187; mbaF-PO1 graphic file with name nihms431679t3.jpg
#1188; mbaS-PO2 graphic file with name nihms431679t4.jpg
#1125; mbaF-PO3 5′-AAGAACGCGAGCTCGG-3′
#1126; mbaS-PO4 5′-GCGGCACTTCGCTCGT-3′
#1219; mbaF-KO1 graphic file with name nihms431679t5.jpg
#1220; mbaS-KO2 graphic file with name nihms431679t6.jpg
#1223; mbaF-KO3 5′-GCAGCGCCGCTTGCCG-3′
#1224; mbaS-KO4 5′-GCCTGCGGCGCGCAC-3′
#1229; mbaS-KO5 graphic file with name nihms431679t7.jpg
#560; Plac-up 5′-GCCCAATACGCAAACCGCCTCTC-3′
#566; Flp-down 5′-TAAATGGATCCTTATATGCGTCTATTTATG-3′
#1221; mbaF-out 5′-GCCGCGCGTTCACCGAAG-3′
#1222; mbaS-out 5′-CTTCGAACGGGGCGTTTG-3′
#1189; mbaS-rev 5′-GACGAGCTTCACGAACAC-3′
#1484; asd-KO1 graphic file with name nihms431679t8.jpg
#1485; asd-KO2 graphic file with name nihms431679t9.jpg
#1486; asd-KO3 5′-TTCAGCACCAGCAACGCG-3′
#1487; asd-KO4 5′-CGCCACCCATCGCGAGCT-3′
#1488; asd-up 5′-ATCTGATCGAGCCGGTG-3′
#1489; asd-down 5′-GTAAATGCCGACAGGTAT-3′
a

Underlined are homologous sequences to targets on the chromosome. Shaded sequences in the long oligos are identical to the shorter oligos used in the second PCR (step 5 of the protocol). In blue are reverse complementary sequences of mbaF-KO1 and mbaS-KO5 where these primers are used to generate ~100 bp PCR product to create the unmarked mutation (step 13A).

In vivo PO strategy

The in vivo cloning or PO protocol involves the amplification of a PCR product from the engineered plasmid pAM3G, containing a glyphosate (GS) resistance selectable marker9, a bhr origin of replication, and an origin of transfer for conjugation (Fig. 1c and 2). The PCR amplified fragment (~2.8 kb), flanked by sequences homologous to the chromosomal PO region, is incubated with cells expressing the λ Red proteins. As examples of the PO protocol, we will individually describe the in vivo cloning of the B. thailandensis arabinose utilization operon (araABCDEFGHI, 11.6 kb)10 and the B. pseudomallei siderophore malleobactin biosynthetic cluster (mba-cluster, 31.5 kb)18 into the pAM3G replicating-plasmid backbone. The PO strategy for the mba-cluster is depicted in Figure 2. Positive PO frequencies of GS resistant colonies with araABCDEFGHI clones ranged from 88% to 93% in B. thailandensis (Table 3), while cloning frequencies for the mba-cluster ranged from 90% to 100% in B. pseudomallei (Table 4).

TABLE 3.

Pull-out recombineering efficiencies of the ara-operon in B. thailandensisa.

DNA amount 1st PCR Productb 2nd PCR Productc
2 μg 41 ± 9 (92%) 245 ± 40 (89%)
0.5 μg 3 ± 1 (92%) 19 ± 3 (90%)
0.1 μg 1 ± 1(100%) 4 ± 0.3 (93%)
a

Each experiment was performed in triplicate, and average number of GS resistant colonies is shown with standard error of the mean. On average, 12 GS resistant colonies were PCR screened for positive pull-out and the percentage is shown in parenthesis.

b

The 1st PCR product, amplified with the non-PAGE purified long oligos, was directly used for PO.

c

The 2nd PCR product, amplified using shorter non-PAGE purified oligos and the 1st PCR product as template, was used for PO.

TABLE 4.

Pull-out /knock-out recombineering efficiencies of the mba cluster in B. pseudomalleia.

DNA amount Pull-out Knock-out
Uninduced Induced Uninduced Induced
2 μg 0 55 ± 11 (90%) 0 45 ± 8 (92%)
0.5 μg ND 19 ± 5 (100%) ND 21 ± 7 (88%)
0.1 μg ND 3 ± 1 (100%) ND 5 ± 2 (92%)
a

Each experiment is performed in triplicate, and average number of GS resistant colonies is shown with standard error of the mean. On average, 12 GS resistant colonies were PCR screened for positive PO/KO and the percentage is shown in parenthesis.

ND, not determined.

Overview of KO strategy

The KO procedure utilizes a PCR amplified pheS-gat FRT-cassette flanked by 40–45 bp of sequence homologous to the targeted chromosomal regions (Fig. 1d). Upon introduction of the pKaKa2 plasmid and induction of the λ Red proteins’ expression, KOs can be achieved in one step by transformation of the PCR-amplified pheS-gat cassette and selection on glyphosate. The helper plasmid pKaKa2 could be cured by counter-selection with sacB on sucrose-containing media (Fig. 1b). Figure 3 depicts an example of chromosomal KO using pKaKa2 in B. pseudomallei at high frequencies (88–92%, Table 4). We foresee that for those laboratories approved to use kanamycin-resistance selection in B. pseudomallei, pKaKa1, in conjunction with the sacB-gat cassette, could be used to generate KO in B. pseudomallei (Fig. 1a and 1d). In this case, pKaKa1 could be cured by counter-selection with pheS on cPhe-containing media.

Figure 3.

Figure 3

KO recombineering strategy. The example shown here involves the amplification of the pheS-gat cassette with Target-KO primers (Fig. 1d) to generate a 1.8 kb PCR product containing 40–45 bp homologous sequences to the end of mbaF and the beginning of mbaS genes. Upon uptake by the natural transformation system of B. pseudomallei and selection with GS, λ Red proteins facilitate the one-step recombination of the PCR product to KO the 31.4 kb mba-cluster on chromosome I. The resulting B. pseudomallei marked mutant strain (Δmba::pheS-gat-FRT), still containing pKaKa2, is re-induced to express λ Red proteins a second time to create unmarked mutants. By transforming a smaller PCR fragment containing 40–45 bp homologies to mbaF and mbaS for recombination, unmarked mutants lacking pheS-gat can be easily selected by counter-selection on cPhe-containing medium. Alternatively, the pheS-gat-FRT cassette can be easily removed by naturally transforming a flp-containing PCR fragment for transient expression. The black horizontal arrows indicate outside primers used to screen for mutants.

Recycling of useful markers

There are very few selectable or counter-selectable markers for genetic manipulation in most bacteria, and the ability to reuse these precious markers in the same strain is essential. This protocol describes two strategies for recycling the pheS-gat or sacB-gat FRT-cassettes (Fig. 3). A second round of λ Red protein induction followed by incubation of cells with a short PCR fragment flanked by 40–45 bp homologous to the targeted region on the chromosome (Fig. 3) will generate an unmarked KO mutant in B. thailandensis or B. pseudomallei. This strategy can be achieved quickly because of the presence of pKaKa1 or pKaKa2 from the prior KO procedure. In an alternative strategy, which does not require λ Red proteins, the unmarked KO mutants can be generated by incubating cells with a PCR fragment containing flp (Fig. 3).

Overview of the Protocol

This pull-out/knock-out protocol is summarized in Figure 4. Steps 1–12 demonstrate the generation of pull-out/knock-out in B. pseudomallei and B. thailandensis (left section). Following knock-out with the pheS/sacB-gat FRT-cassette, unmarked mutations can be created with overlapping oligos (middle; step 13A) or Flp-mediated excision (right; step 13B). When desired, the helper plasmid can be cured via pheS/sacB counter-selection (step 14). The step-by-step protocol is described below.

Figure 4.

Figure 4

λ red recombineering scheme for PO/KO in B. thailandensis and B. pseudomallei. Strategy for PO/KO recombineering is shown on the left, whereas the middle or right sections present the strategies for creating unmarked mutants via λ red recombination or Flp-mediated excision, respectively. Detailed descriptions for each step are provided in the procedure. In red are numbers that correspond to the steps in the protocol.

MATERIALS

REAGENTS

  • Amino acids: 2,6-diaminopimelic acid (100 mg ml−1 in 1 M NaOH, e.g., Acros Organics cat. no. 235540010); L-leucine (1 M filter sterilized, e.g., Acros Organics cat. no. 125121000); L-lysine (1 M filter sterilized, e.g., Acros Organics cat. no. 303340050), L-methionine (1 M filter sterilized, e.g., Acros Organics cat. no. 166160250), L-threonine (1 M filter sterilized, e.g., Acros Organics cat. no. 138930050), and L-tryptophan (1 M filter sterilized, e.g., Acros Organics cat. no. 140591000)

  • Bacterial Strains:

  • Burkholderia strains (Table 1)

  • Burkholderia thailandensis E264 (available from BEI Resources)

  • Burkholderia pseudomallei 1026b, Bp0085, Bp0091, Bp0094, Bp4001, Bp4003, Bp4122, Bp4141, Bp4144, Bp6340

    ! CAUTION Acquisition, possession, and manipulation of B. pseudomallei strains in the United States are limited to FBI screened and cleared personnel and experiments must be performed in CDC/USDA approved and registered BSL-3 select agent facilities.

  • E. coli strains (Table 1; available from T.T.H.)

  • Plasmids (Table 1; available from T.T.H.):

  • pKaKa1 or pKaKa2, replicating plasmids containing inducible λ Red genes (Fig. 1)

  • pAM3G, broad host-range plasmid encoding gat (glyphosate acetyl-transferase), source of PCR fragment for pull-out recombineering

  • pwFRT-PCS12-pheS-gat or pwFRT-PCS12-sacB-gat plasmid DNA used as template for knockout recombineering

  • pCD13SK-Flp-oriT-asdEc plasmid DNA used as template to amplify flp gene containing fragment

  • Oligonucleotides (see Table 2) (Integrated DNA Technologies)

  • Target-PO1 (5′-N40-GATTCCTTAAGGTATACTTT-3′)

  • Target-PO2 (5′-N40-ACGGCCTCTAGGCCAGATCC-3′)

  • Target-PO3 (N16–20 identical to the 5′-end of Target-PO1)

  • Target-PO4 (N16–20 identical to the 5′-end of Target-PO2)

  • Target-rev (N16–20 anneals inside of the PO region, use with oligo ori1600-rep-internal to PCR confirm PO)

  • ori1600-rep-internal (5′-GGAAGATTTCAGATGCTGAG-3′, use with oligo Target-rev to PCR confirm PO)

  • Target-KO1 (5′-N40-CAAGGCGATTAAGTTGGGTA-3′)

  • Target-KO2 (5′-N40-GCTCGTATGTTGTGTGGAATTGTGA-3′)

  • Target-KO3 (N16–20 identical to the 5′-end of Target-KO1)

  • Target-KO4 (N16–20 identical to the 5′-end of Target-KO2)

  • Target-KO5 (5′-N40-TACCCAACTTAATCGCCTTG-3′; this oligo has identical N40 as Target -KO2)

  • Above: N40 refers to 40 bases of sequence homologous to your target gene, where underlined bases can be common to the target and also anneal to the PCR template to increase efficiency and reduce costs.

  • Target-up-out (N16–20 anneals outside of the homologous region, use with Target-down-out to PCR confirm KO)

  • Target-down-out (N16–20 anneals outside of the homologous region, use with Target-up-out to PCR confirm KO)

  • Plac-up (5′-GCCCAATACGCAAACCGCCTCTC-3′)

  • Flp-down (5′-TAAATGGATCCTTATATGCGTCTATTTATG-3′)

  • DMSO (e.g., Acros Organics cat. no. 295520010)

  • 100 bp DNA ladder (range 100 to 1,500 bp, e.g., New England Biolabs, cat. no. N3231L)

  • 1 kb DNA ladder (range 0.5 to 10 kb, e.g., New England Biolabs, cat. no. N3232L)

  • dNTPs (2 mM; e.g., New England Biolabs, cat. no. N0447L)

  • LB agar Lennox and LB broth Lennox (e.g., Teknova, cat. nos. L9330 and L9310)

  • LS agar (LB agar without NaCl; e.g. Teknova, cat. no. L9200)

  • Saccharides: L-arabinose (2 M filter sterilized; e.g., MP Biomedicals, cat. no. 10076); L-rhamnose (10% (w/v) filter sterilized; e.g., Sigma-Aldrich, cat. no. R3875); D-glucose (1 M filter sterilized; e.g., Sigma-Aldrich, cat. no. G7528); Sucrose (1 M filter sterilized; e.g., Tekanova, cat. no. S0002)

  • DL-chlorinated phenylalanine (cPhe; e.g., Acros Organics, cat. no. 15728-0050)

  • Enzyme: Pfu polymerase (e.g., Stratagene, cat. no. 600153)

  • CaCl2 (1 M, autoclaved in water; e.g., Acros Organics, cat. no. 194635)

  • MgSO4 (1 M, autoclaved in water; e.g. Acros Organics, cat. no. 194699)

  • M9 minimal salts (5×, e.g., Sigma-Aldrich, cat. no. M6030); alternative preparation19

  • Agar (molecular biology grade; e.g., Teknova cat. no. A777)

  • Agarose (molecular grade; e.g. Research Products International, cat. no. A20065-100.0)

  • Glyphosate, super-concentrated Round Up® (50% (v/v) GS from Home Depot or other farm/garden supply stores)

EQUIPMENT, SUPPLIES, AND FACILITIES

  • 0.22 μm pore size syringe filters (25 mm diameters; e.g., Fisher Scientific cat. no. 09-719E)

  • 1.5 ml microcentrifuge tubes (e.g., Corning cat. no. 3621)

  • 1–200 μl beveled pipet tips (sterile; e.g., Fisher Scientific cat. no. 02-707-450)

  • 37°C incubators

  • Aerosol barrier plug tips, 200 μl and 1000 μl (sterile; e.g., Genesee Scientific cat. no. 24-412 and 24-430)

  • Biosafety level three (BSL-3) laboratory (inspected and approved by CDC/USDA) and practices as recommended by the Biosafety in Microbiological and Biomedical Laboratories, 5th edition20. Although non-antibiotic markers and the kanamycin resistance marker are described in this protocol, prior approval for their use in B. pseudomallei must be sought with the CDC/USDA for work performed or funded by federal agencies within the United States.

  • Culture tubes (14 ml, sterile disposable, snap cap; e.g. BD Falcon cat. no. 352018)

  • DNA purification kits: plasmids isolation kit (e.g., Zyppy Plasmid Miniprep Kit cat. no. D4036); gel DNA recovery kit (e.g., Zymoclean Gel DNA Recovery Kit cat. no. D4001); DNA cleanup kit (e.g., Zymoclean DNA Clean & Concentrator Kit cat. no. D4003)

  • Electroporation cuvettes (2 mm gap; e.g., Genesee Scientific cat. no. 40-101)

  • Electroporator (e.g., Bio-Rad Gene Pulser Xcell with pulse control module cat. no. 165-2662)

  • Falcon tubes (15ml, conical, screw cap, sterile, disposable; e.g., BD Falcon cat. no. 352097)

  • Gradient cycler (e.g., Eppendorf Mastercyler gradient)

  • Inoculation loop (e.g., Fisher Scientific cat. no. 130753)

  • Micro-centrifuge (e.g., Eppendorf Mini-Spin Plus cat. no. 5453-000.011)

  • Petri dish (e.g., Fisher Scientific cat. no. 08-757-12)

  • Spectrophotometer (e.g., Eppendorf Biophotometer cat. no. 6131 000.020)

  • Vacuum concentrator (e.g., Thermal Scientific SpeedVac cat. no. DNA120-115)

REAGENT SETUP

Agarose gels

Agarose gels are prepared by adding molecular grade agarose to 100 ml of 1× TAE buffer19 to obtain desired concentrations. The mixture is then heated and allowed to cool in a gel mold. The agarose gels are prepared freshly before use.

Antibiotic stock and nutrient solution preparation

Prepare stock solutions of D-glucose (1 M), kanamycin (35 mg ml−1), L-arabinose (2 M), CaCl2 (1 M), MgSO4 (1 M), and L-rhamnose (10%). Dissolve all compounds in the appropriate amounts of double distilled water (DDW). The arabinose, kanamycin, glucose, and rhamnose solutions should be passed through 0.2 μm syringe filters to sterilize. 5× M9 minimal salts solution is prepared by autoclaving the 5×salt mixture with the appropriate volume of DDW. The 1 M CaCl2 and 1 M MgSO4 can be autoclaved separately to sterilize. Store the kanamycin stock solution at 4°C. The sugar and salt solutions can be stored at room temperature for several months.

Liquid media preparation

Use LB broth to prepare rich media. To prepare 1 liter of M9 glucose (MG) medium, add 200 ml 5× M9 minimal salts solution, 20 ml 1 M glucose, 500 μl 1 M MgSO4, 25 μl CaCl2, and 780 ml sterile DDW. Final concentrations are: 1× M9 minimal salts, 20 mM glucose, 500 μM MgSO4, and 25 μM CaCl2. One liter of M9 arabinose (MA) medium is made by adding 200 ml 5× M9 minimal salts solution, 20 ml 2 M arabinose, 500 μl 1 M MgSO4, 25 μl CaCl2, and 780 ml sterile DDW. Final concentrations are: 1× M9 minimal salts, 40 mM arabinose, 500 μM MgSO4, and 25 μM CaCl2. The liquid media can be made and stored at room temperature for several months.

Solid media preparation

All solid media could be made fresh or stored at 4°C for several months. Use LB or LS agar to prepare rich plate media. One liter of M9 glucose (MG) or M9 arabinose (MA) with agar is made by first preparing 15 g agar in 780 ml DDW and sterilizing. After autoclaving, add 200 ml 5× M9 minimal salts solution, 20 ml 1 M glucose or 20 ml 2 M arabinose. Let it cool to ~50 °C before adding 500 μl 1 M MgSO4 and 25 μl CaCl2. The final concentrations are: 1.5% (w/v) agar, 1× M9 minimal salts, 20 mM glucose or 40 mM arabinose, 500 μM MgSO4, and 25 μM CaCl2. Approximately 50 plates could be made from 1 liter of medium. When growing B. pseudomallei asd-specific mutant in minimal medium (Table 1 and Fig. 7), Met, Lys, and Thr are added at final concentration of 1 mM, and DAP was added at 200 μg/ml. Sucrose is added at a concentration of 15% (w/v). cPhe is added at a concentration of 0.1% (w/v) as previously described8.

Figure 7.

Figure 7

KO recombineering in different B. pseudomallei strains. (a) Various B. pseudomallei clinical and environmental isolates were incubated with gfp-containing PCR product to confirm their natural competency. After DNA incubation and 45 min recovery in LB, transient expression of GFP was observed for all nine naturally transformable strains (Table 1) and representative images are shown for one of these strains. The other 11 B. pseudomallei strains tested did not show fluorescent baceria and presumably are not naturally competent (data not shown). Abbreviation: DIC, differential interference contrasts. White scale bars equal 10 μm in length. (b) Successful KO of the asd gene in 1026b strain and the nine newly identified naturally transformable B. pseudomallei strains were confirmed by PCR with oligos annealing outside of the asd gene on the chromosome, and one isolate from each strain is shown. W: wildtype; M: mutant; L, 1 kb DNA ladder from New England Biolabs. The ~2.1 kb PCR products obtained in all mutant strains are results of pheS-gat insertion in the asd region indicated by the ~1.1 kb PCR fragment in the corresponding wild-type strains.

PROCEDURE

Preparing pull-out/knock-out DNA fragment ● TIMING 1 d

  • 1

    Design oligonucleotide primers such that the last 45 bases on the 5′ end are homologous to two corresponding regions on the chromosome for the pull-out/knock-out method and order oligos prior to initiating the protocol. When designing the pair of pull-out or knock-out oligos, avoid five consecutive matching base pairs between them within their 5′ ends to prevent intra-fragment recombination2. All oligos do not require PAGE purification, however, the majority of the long oligos (60–65 bp) produced will be truncated or have incorrect 5′-ends since the coupling or synthesis efficiency is not 100% (coupling efficiencies are available from oligo manufacturer), resulting in reduced recombineering efficiency (e.g., approximately 29% of the 60 bp oligos have truncated or incorrect ends when the coupling efficiency is 99%, or up to 95% will have truncated or incorrect ends if coupling efficiency is as low as 95%). To remedy this problem and increase recombineering efficiency at reduced cost, a two-step PCR approach is described below. The 1st PCR product is obtained using the long oligos, which is used as the template for subsequent amplification by shorter oligos (16 – 20 bp) annealing to the 5′-ends of the 1st PCR product. The shorter oligos required for the second PCR should have identical sequences as the 5′-end of the long oligos from the 1st PCR, which would repair and yield more correct 5′-ends (Fig. 1 and Table 2). ● TIMING 1 h

  • 2

    Set up one PCR reaction using the long oligos and the following components in a thin-walled PCR tube. ●TIMING 10 min

    Component Amount (μl) Final
    ddH2O 35.0 -
    10× Pfu buffer 5.0
    dNTPs (2 mM) 5.0 0.2 mM
    pAM3G or pwFRT-pheS/sacB-gat DNA (~20 ng μl−1) 1.0 ~20 ng
    Target-PO1 or Target-KO1 (30 μM) 1.0 30 pmol
    Target-PO2 or Target-KO2 (30 μM) 1.0 30 pmol
    Pfu polymerase (2.5 U μl−1) 2.0 5 U

    ▲ CRITICAL STEP It is essential to use Pfu polymerase or other polymerases that generate blunt-ends to avoid the addition of unwanted bases (e.g. A at the 3′-end with Taq). The proofreading capability of Pfu polymerase will also significantly increase the fidelity of the PCR products.

  • 3

    Carry out the PCR as below: ● TIMING 4 h

    Set the lid temperature to 98°C to prevent condensation of the sample during the reaction.

    Cycle Number Denaturation Annealing Extension Termination
    1 94°C, 2 min
    2–34 94°C, 30 s 58°C, 30 s 72°C, 3 min (pAM3G) or 2 min (pwFRT-pheS/sacB-gat)
    35 72°C, 5 min
    36 4°C, hold

    ■ PAUSE POINT PCR samples can be left in the PCR machine or stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • 4

    Visualize all PCR reactions via agarose gel electrophoresis using a 1.0% agarose gel submerged in TAE buffer (see REAGENT SETUP). If oligos are designed as recommended, PCR products of ~2.7 kb (oriT-ColE1ori-gat-ori1600-rep from pAM3G template) or ~1.8/2.3 kb (pheS/sacB-gat from pwFRT-pheS/sacB-gat template) can be expected. Purify DNA from the gel with desired kit/protocol and quantify using a spectrophotometer at 260 nm. This 1st PCR product could be used directly for recombineering in B. thailandensis with lower frequencies compared to the 2nd PCR product (Table 3), however, the 1st PCR product should not be used directly for B. pseudomallei due to the lower frequencies obtained (Table 4). ● TIMING 2.5 h

    ■ PAUSE POINT If not used for transformation immediately, the DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • 5

    Set up the second PCR using the product from step 4 as template. Typically, set up four PCR reactions to obtain sufficient amounts of DNA, using the shorter oligos as below. Multiply all of the following components by four and combine in a master mix. Pipet 50 μl of the master mix into four thin-walled PCR tubes.● TIMING 30 min

    Component Amount (μl) Final
    ddH2O 35.0 -
    10× Pfu buffer 5.0
    dNTPs (2 mM) 5.0 0.2 mM
    oriT-ColE1ori-gat-ori1600-rep or pheS/sacB-gat DNA (~20 ng μl−1) 1.0 ~20 ng
    Target-PO3 or Target-KO3 (30 μM) 1.0 30 pmol
    Target-PO4 or Target-KO4 (30 μM) 1.0 30 pmol
    Pfu polymerase (2.5 U μl−1) 2.0 5 U

    ▲ CRITICAL STEP It is essential to use Pfu polymerase or other polymerases that generate blunt-ends to avoid the addition of unwanted bases. The proofreading capability of Pfu polymerase will significantly increase the fidelity of the PCR products.

  • 6

    Carry out the PCR as below: ● TIMING 4 h

    Set the lid temperature to 98°C to prevent condensation of the sample during the reaction.

    Cycle Number Denaturation Annealing Extension Termination
    1 94°C, 2 min
    2–34 94°C, 30 s 58°C, 30 s 72°C, 3 min (pAM3G) or 2 min (pwFRT-pheS/sacB-gat)
    35 72°C, 5 min
    36 4°C, hold

    ■ PAUSE POINT PCR samples can be left in the PCR machine or stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • 7

    Visualize all PCR reactions via agarose gel electrophoresis using a 1.0% agarose gel submerged in TAE buffer (see REAGENT SETUP). If oligonucleotides are designed as recommended, PCR products of ~2.7 kb (oriT-ColE1ori-gat-ori1600-rep fragment) or ~1.8/2.3 kb (pheS/sacB-gat FRT-cassette) can be expected. Purify DNA from all bands produced with desired kit/protocol and quantify using a spectrophotometer at 260 nm. ● TIMING 2.5 h ?

    TROUBLESHOOTING

    ■ PAUSE POINT If not used for transformation immediately, the DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

    ALTERNATIVE STRATEGY If cost is not an issue, PAGE purified long oligos could be ordered and the 1st PCR product could be used directly for recombineering without the need for a 2nd PCR. The PCR with PAGE purified long oligos should be set up exactly as the 1st PCR.

Introduction of pKaKa1/pKaKa2 into Burkholderia species

  • 8

    The plasmids encoding λ red proteins are pKaKa1 (for B. pseudomallei and B. thailandensis) and pKaKa2 (for B. pseudomallei). One of these plasmids should be introduced into bacteria prior to PO/KO experiments, via electroporation or conjugation. Option A describes delivery of pKaKa1 by electroporation. pKaKa1 contains the kanamycin resistance marker and selection is performed on LB + Km500 for B. thailandensis, or LB + Km1000 for B. pseudomallei21. Delivery of pKaKa2 by electroporation or conjugation is described in Option B or C, respectively. pKaKa2 confers arabinose utilization ability to B. pseudomallei and is selected for on MA medium. The conjugation method (Option C) is particularly useful for delivering plasmid into the select agent B. pseudomallei, as it reduces the risk of generating aerosols during electroporation. Although we only describe the mating protocol for pKaKa2 into B. pseudomallei, but conjugation of pKaKa1 into B. pseudomallei could be done similarly. For KO in B. pseudomallei, the pKaKa1 helper plasmid should be used in conjunction with the sacB-gat fragment, while pKaKa2 should be used with pheS-gat fragment.

Option A. Electroporation of pKaKa1 into B. thailandensis or B. pseudomallei ● TIMING 4 d

  • (i)

    Grow 5 ml of B. thailandensis or B. pseudomallei in LB broth from a single colony overnight at 37°C in a shaking incubator set to 225 r.p.m. ● TIMING ~10 min; end of day 1

  • (ii)

    After the culture has reached a sufficient density (OD600 0.8–1.5), spin down all 5 ml in a mini-centrifuge at 10,000 g for 1 min. Wash the cell pellet with 1 ml of cold, sterile ddH2O. Repeat this 4 more times adhering to the same centrifugation conditions. ● TIMING ~20 min

    ! CAUTION Pipette and wash gently to minimize aerosolization of B. pseudomallei culture. Filtered pipette tips should be used for B. pseudomallei to avoid contamination of the pipette.

  • (iii)

    Remove all water from the washed pellet and resuspend the cell pellet with 40 μl of cold, sterile ddH2O. Add 1 μl of purified pKaKa1 plasmid DNA (0.2–0.5 μg) to the competent cells and transfer the mixture to an electroporation cuvette. Place the eletroporation cuvette in the electroporator shock chamber and apply a shock of 2.5 kV, 25 μF, 200 Ω. Ensure an exponential decay of the applied shock and the absence of an arc. ● TIMING ~1 h

    ? TROUBLESHOOTING

  • (iv)

    Immediately add 1 ml of rich broth media (e.g., LB broth) to the cuvette and transfer to a round bottom culture tube. Incubate the culture for 1 h at 37°C with shaking at 225 r.p.m. to allow for kanamycin resistance gene expression (Fig. 1a). ● TIMING ~1 h

  • (v)

    Pipet 100 μl of the recovery mixture onto an LB + Km500 (B. thailandensis) or LB + Km1000 (B. pseudomallei) plate while centrifuging the rest of the recovered culture at 16,000 g for 1 min prior to plating. Remove all but 100 μl of media, then spread the remaining culture on another LB + Km plate. Incubate both plates in a 37°C incubator until colonies appear ~2 d later.● TIMING ~2 d

    ALTERNATIVE STRATEGY Instead of using cold ddH2O, room temperature 300 mM sucrose may be substituted when washing cells as previously described15. Comparable electroporation efficiencies can be obtained using either method.

Option B. Electroporation of pKaKa2 into B. pseudomallei ● TIMING 4 d

  • (i)

    In a 15 ml Falcon tube, grow B. pseudomallei in 5 ml of LB broth overnight at 37°C in a shaking incubator set to 225 r.p.m. ● TIMING ~10 min; end of day 1

  • (ii)

    After the culture has reached a sufficient density (OD600 0.8–1.5), spin down all 5 ml in a mini-centrifuge at 10,000 g for 1 min. Wash the cell pellet with 1 ml of cold, sterile ddH2O. Repeat this 4 more times adhering to the same centrifuge conditions. ● TIMING ~2 h

  • (iii)

    Remove all water from the washed pellet and resuspend the cell pellet with 40 μl of cold, sterile ddH2O. Add 1 μl of purified pKaKa2 plasmid (~0.2 μg) DNA to the competent cells and transfer the mixture to an electroporation cuvette. Place the eletroporation cuvette into the electroporator shock chamber and apply a shock of 2.5 kV, 25 μF, and 200 Ω. Ensure an exponential decay of the applied shock and the absence of an arc. ● TIMING ~0.5 h ?

    TROUBLESHOOTING

  • (iv)

    Immediately add 1 ml of rich broth media (e.g., LB broth) to the cuvette and transfer to a 15 ml culture tube with a screw cap. Incubate the culture for 1 h at 37°C with shaking at 225 r.p.m. for recovery. ● TIMING ~2 h

  • (v)

    Transfer the recovery mixture into a 1.5 ml microcentrifuge tube and spin in a mini-centrifuge at 10,000 g for 1 min. Discard the supernatant, wash the cell pellet twice with 1 ml of 1× M9 buffer, and resuspend the cell pellet in the same volume of 1× M9 buffer. Plate 100 μl of the resuspended cells onto an MA agar plate, while centrifuging the rest at 16,000 g for 1 min. Remove all but 100 μl of buffer, then spread the remaining culture on another MA agar plate. Incubate both plates in a 37°C incubator until colonies appear ~2 d later. ● TIMING ~2 d

    ALTERNATIVE STRATEGY Instead of using cold ddH2O, room temperature 300 mM sucrose may be substituted when washing cells as previously described15. Comparable electroporation efficiencies can be obtained using either method.

Option C. Conjugation of pKaKa2 into B. pseudomallei ● TIMING 3 d

  • (i)

    Grow a single colony of B. pseudomallei in 2 ml of LB broth, and the E. coli donor harboring pKaKa2 (E1354/pKaKa2) in 2 ml of MA + 1 mM Leu + 1 mM Lys + 1 mM Met + 1 mM Thr + 1 mM Trp + 100 μg ml−1 DAP, overnight at 37°C in a shaking incubator set to 225 r.p.m. ● TIMING ~10 min; end of day 1

  • (ii)

    After both cultures have reached a sufficient density (OD600 0.8–1.5), spin down 1 ml of each culture separately in a mini-centrifuge at 10,000 g for 1 min. Remove all medium from the E. coli donor and all but 40 μl LB from the B. pseudomallei tube, and resuspend both pellets in this 40 μl of LB. Spot this 40 μl mixture on the surface of a dried and prewarmed (37°C) LB agar plate, and incubate at 37°C for 4 h. ● TIMING ~4.5 h

  • (iii)

    Gently scrape the cells off the plate with sterile inoculation loop and resuspend in 1 ml of 1× M9 in a 1.5 ml microcentrifuge tube, spin in a mini-centrifuge at 10,000 g for 1 min. Discard the supernatant, wash the cell pellet once more with 1 ml of 1× M9 buffer, and resuspend the cell pellet in the same volume of 1× M9 buffer. Plate 100 μl of the resuspended cells onto an MA agar plate, and incubate in a 37°C incubator until colonies appear ~2 d later. ● TIMING ~2 d

Induction of λ red protein expression ● TIMING ~18 h

  • 9

    The λ red proteins encoded on A, pKaKa1, and B, pKaKa2 require different induction conditions as detailed below. Option A describes the induction of the λ Red proteins encoded on pKaKa1 with arabinose. Option B describes the induction of the λ Red proteins encoded on pKaKa2 with rhamnose.

Option A. Induction of the λ Red proteins encoded on pKaKa1

  • (i)

    Grow the colonies of B. thailandensis or B. pseudomallei harboring pKaKa1 in 4 ml of LB broth containing Km 300 or 1000, respectively. ● TIMING ~12 h

  • (ii)

    When the culture grows to an OD600 of ~1.4 (B. thailandensis) or ~0.8 (B. pseudomallei), add arabinose to a final concentration of 10 mM to induce the λ red system on pKaKa1. After ~4 h of induction, harvest the culture by centrifugation. Concentrate the culture ~200 times by resuspending all cell pellets in 20 μl of LB broth. Incubate the resuspended cells with DNA obtained in step 7 immediately. ● TIMING ~5 h

    ▲ CRITICAL STEP Induction at the proper OD is crucial for efficient recombineering. If the OD is too low, toxicity of λ red proteins can cause the cells to stop growing. If the OD is too high, cells tend to be “unhealthy” after induction and recombineering efficiencies decrease.

Option B. Induction of the λ Red proteins encoded on pKaKa2

  • (i)

    Grow the colonies of B. pseudomallei harboring pKaKa2 in 4 ml of MA at 37°C with shaking at 225 r.p.m. ● TIMING ~12 h

  • (ii)

    When the culture grows to an OD600 of ~0.8, add rhamnose to a final concentration of 0.2% to induce the λ red system on pKaKa2. After ~4 h of induction, harvest the culture by centrifugation. Concentrate the culture ~200 times by resuspending all cell pellets in a 20 μl volume of LB broth. Incubate the resuspended cells with DNA obtained in step 7 immediately. ● TIMING ~5 h

    ▲ CRITICAL STEP Induction at the proper OD is crucial for efficient recombineering. If the OD is too low, toxicity of λ red proteins can cause the cells to stop growing. If the OD is too high, cells tend to be “unhealthy” after induction and recombineering efficiencies decrease.

DNA incubation ● TIMING ~4 d

  • 10

    Add 0.5–2.0 μg of PO/KO DNA obtained in step 7 of the protocol, depending on the desired frequency (Tables 3 and 4), to a 20 μl aliquot of induced and concentrated cells. Incubate the cultures for 30 min at room temperature without shaking. After 30 min add 2 ml of LB, incubate at 37°C with shaking at 225 r.p.m. for 1 h. ● TIMING ~1.5 h

    ▲CRITICAL STEP A small volume of the DNA sample (≤10 μl) should be added to the concentrated cells as close contact between the cells and DNA is critical for efficient DNA uptake. If the volume of the DNA sample exceeds 10 μl, dry it down in a vacuum concentrator.

  • 11

    Pipet the recovery mix into a 1.5 ml microcentrifuge tube and centrifuge at 16,000 g for 1 min. Wash the pellet twice with 1 ml of 1× M9. Remove 800 μl of the 1× M9 and resuspend the cell pellet in the remainder of the M9. Pipet and spread 50 μl and 150 μl of the recovery onto two different MG plates containing 0.04% GS for B. thailandensis or 0.3% GS for various strains of B. pseudomallei (with the exception of strain Bp0091 where 0.1% GS was used). Colonies should be visible in ~3 d. ● TIMING ~3 d

PCR Screening for successful pull-out/knock-out

  • 12

    The screening for correct clones for pull-out (option A) or knock-out (option B) is done differently as detailed below.

Option A. Pull-out screen in B. thailandensis and B. pseudomallei ● TIMING ~3 d

  • (i)

    Single colonies, containing the pull-out fragment as a replicating plasmid, should appear with a frequency similar to those shown in Table 3 or 4 (Typically, when 0.5–2 μg PO DNA was used, 20–200 colonies should be expected for B. thailandensis or 20–60 colonies for B. pseudomallei). To verify a positive pull-out, a Target-rev gene specific oligonucleotide (e.g. araI-rev or mbaS-rev) and a pAM3G specific oligonucleotide (e.g. ori1600-rep-internal) should be used for PCR verification (Table 2 and Fig. 5). PCR verification should be set-up exactly as described above in steps 2–3 with extension time ~1 min/kb. ● TIMING ~4 h

    ? TROUBLESHOOTING

  • (ii)

    Once a successful pull-out of the desired fragment is verified, inoculate the positive colonies into liquid MG + 0.01% GS (B. thailandensis) or MG + 0.1% GS (B. pseudomallei). Isolate the plasmid with a plasmid isolation kit and electro-transform into an E. coli cloning strain (e.g., EPMax-10B or E1889 in Table 1) for maintenance and downstream manipulation. Electro-transformation of E. coli is described elsewhere8. ● TIMING ~2 d

    ? TROUBLESHOOTING

    ALTERNATIVE STRATEGY Instead of purifying plasmids from liquid culture, pipet 100 μl of the culture into a 1.5 ml micro-centrifuge tube and boil the tube for 8 min. Centrifuge the tube at 16,000 g for 1 min to spin down the cell debris. Electroporate 5 μl of the boiled supernatant into an electrocompetent E. coli cloning strain (e.g., EPMax-10B or E1889 in Table 1) for further downstream applications.

Figure 5.

Figure 5

PCR confirmation for pull-out/knock-out in B. thailandensis and B. pseudomallei. (a) As an example, the arabinose utilization operon was pulled-out from the B. thailandensis chromosome using the pAM3G backbone with 45 bp homologous sequences to the araA and araI genes. The genetic map of the resulting plasmid is shown with the oligos in blue used for PCR screening. Using these oligos, 10 independent pull-outs were screened by PCR. As indicated by the arrow, a PCR product with the correct size was obtained in 89% (8 out of 9) of the GS resistant colonies. Abbreviations: NC, negative control using wildtype B. thailandensis as template; L, 1 kb DNA ladder from New England Biolabs. (b) Similarly, the mba cluster was pulled-out from the B. pseudomallei strain 1026b chromosome, and the genetic map of the resulting plasmid, pAM3G-mba, was shown with the oligos in blue used for PCR screening. Using these oligos, 10 independent pull-outs were screened by PCR. As indicated by the arrow, PCR products with the correct size were obtained in 90% (9 out of 10) of the GS resistant colonies.

Option B. Knock-out screen in B. pseudomallei ● TIMING ~5 h

  • (i)

    Single colonies, with the pheS/sacB-gat fragment recombined into the chromosome deleting the target gene, should appear with a similar frequency as shown in Tables 4 and 5 (Typically, when 0.5–2 μg KO DNA was used, 20–50 colonies should be expected). To verify a successful knock-out, a set of Target-up-out and Target-down-out oligos annealing to chromosomal regions outside of the targeted KO primers are used (e.g. mbaF-out and mbaS-out, Table 2). PCR verification should be set-up exactly as described above in steps 2–3 with extension time ~1 min/kb. ● TIMING ~4 h

    ? TROUBLESHOOTING

  • (ii)

    Upon verification of the knock-out, it is critical to purify the positive colonies on MG + GS plate once before growth for storage. If unmarked mutations are desired, ensure the mutant still harbors pKaKa2 by growing in MA broth or pKaKa1 by growing in LB + Km1000 broth, and follow step 13 below to remove the pheS/sacB-gat fragment from the mutant chromosome. ● TIMING ~10 min

TABLE 5.

Knock-out recombineering efficiencies of the essential asd gene in various naturally transformable clinical and environmental B. pseudomallei isolatesa.

λ-red 1026b Bp0085 Bp0091 Bp0094 Bp4001 Bp4003 Bp4122 Bp4141 Bp4144 Bp6340
Uninduced 0 0 0 0 0 0 0 0 0 0
Induced 144 (100%) 22 (76%) 34 (88%) 15 (80%) 13 (69%) 26 (85%) 89 (53%) 52 (82%) 64 (62%) 23 (87%)
a

Two μg of DNA (pheS-gat cassette flanked by asd homologous regions) was used for each incubation. Mutants were selected on MG + GS plates supplemented with 1 mM of Met, Thr, and Lys, and 200 μg/ml DAP specific for this mutation. GS was used for gat-selection at final concentration of 0.3% (w/v) in all strains, with the exception of 0.1% GS used for Bp0091. Twenty GS resistant colonies were tested phenotypically and by PCR confirmation with external chromosomal primers, and the frequencies of true mutants are shown in parentheses.

(OPTIONAL) Recycling of the pheS/sacB-gat markers for KO in B. pseudomallei ● TIMING 3 d

  • 13

    The pheS/sacB-gat fragment can be removed from the mutant obtained in step 12 by two different strategies. Option A describes replacement of the pheS-gat or sacB-gat cassette by a small PCR fragment homologous to the target gene, via λ red recombination, generating a markerless mutant. Option B describes Flp-mediated excision of the pheS-gat or sacB-gat fragment, generating an unmarked mutant with a single FRT scar remaining in the target gene.

Option A. Replacement of the pheS-gat or sacB-gat cassette with overlapping oligos

  • (i)

    Inoculate the purified colony obtained in step 12B(ii) into 4 ml of MA broth (B. pseudomallei with pKaKa2 and the pheS-gat cassette) or 4 ml of LB + Km1000 broth (B. pseudomallei with pKaKa1 and the sacB-gat cassette) and incubate at 37°C with shaking at 225 r.p.m. When the culture grows to an OD600 of ~0.8, add rhamnose to a final concentration of 0.2% (B. pseudomallei with pKaKa2 and the pheS-gat cassette) or arabinose to a final concentration of 10 mM (B. pseudomallei with pKaKa1 and the sacB-gat cassette) to induce the λ red system. After 4 h of induction, harvest all 4 ml of culture by centrifuging at 16,000 g for 1 min. Discard the supernatant and resuspend the cell pellet in 20 μl of LB. Incubate the resuspended cells with DNA obtained in step 13A(iv) below immediately. ● TIMING ~8 h

    ▲CRITICAL STEP Induction at the proper OD is crucial for efficient recombineering. If the OD is too low, toxicity of λ red proteins can cause the cells to stop growing. If the OD is too high, cells tend to be “unhealthy” after induction and recombineering efficiencies decrease.

  • (ii)

    Typically, set up two PCR reactions to obtain sufficient amounts of DNA, using the overlapping primers. Multiply all of the following components by two and combine in a master mix. Pipet 50 μl of the master mix into two thin-walled PCR tubes. ● TIMING ~30 min

    Component Amount (μl) Final
    ddH2O 30.0 -
    10× Pfu buffer 5.0
    dNTPs (2 mM) 5.0 0.2 mM
    * Target-KO1 (1 μM) 1.0 1 pmol
    * Target-KO5 (1 μM) 1.0 1 pmol
    Target-KO3 (30 μM) 3.0 30 pmol
    Target-KO4 (30 μM) 3.0 30 pmol
    Pfu polymerase (2.5 U μl−1) 2.0 5 U
    *
    Target-KO1 and Target-KO5 anneal to each other and serve as template.

    ▲CRITICAL STEP It is essential to use Pfu polymerase or other polymerases that generate blunt-ends to avoid the addition of unwanted bases. The proofreading capability of Pfu polymerase will significantly increase the fidelity of the PCR products.

  • (iii)

    Carry out the PCR as below: ● TIMING ~4 h

    Set the lid temperature to 98°C to prevent condensation of the sample during the reaction.

    Cycle Number Denaturation Annealing Extension Termination
    1 94°C, 2 min
    2–34 94°C, 30 s 58°C, 30 s 72°C, 30 s
    35 72°C, 5 min
    36 4°C, hold

    ■ PAUSE POINT At this time, the DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • (iv)

    Visualize PCR reactions via agarose gel electrophoresis using a 2.0% agarose gel submerged in TAE buffer (see REAGENT SETUP). A single PCR product of ~100 bp should be observed. Recover and purify DNA from the gel with desired kit/protocol and quantitate using a spectrophotometer. ● TIMING ~2.5 h

    ■ PAUSE POINT The DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • (v)

    Add 0.5–1.0 μg of PCR DNA (~10 μl) obtained in step 13A(iv) to the 20 μl of resuspended cells from step 13A(i). Incubate the mixture for 30 min at room temperature without shaking. After 30 min, add 2 ml of LB and incubate at 37°C with shaking at 225 r.p.m. for 2 h. ● TIMING ~2.5 h

    ▲ CRITICAL STEP A small volume of the DNA sample (≤ 10 μl) should be added to the concentrated cells, as close contact between the cells and DNA is critical for efficient uptake of DNA. If the volume of the DNA sample exceeds 10 μl, dry it down in a vacuum concentrator.

  • (vi)

    Aliquot the recovery mix into two 1.5 ml microcentrifuge tubes and centrifuge at 16,000 g for 1 min. Combine the pellet and wash it twice with 1 ml of 1× M9. Remove 800 μl of the 1× M9 and resuspend the cell pellet in the remainder of the 1× M9. Spread 50 μl and 150 μl of the cel suspension onto two MG plates containing 0.1% cPhe (B. pseudomallei with pKaKa2 and the pheS-gat cassette) or two LS + 15% sucrose plates (B. pseudomallei with pKaKa1 and the sacB-gat cassette) (see REAGENT SETUP). Colonies should be visible in ~2 d. ● TIMING ~2 d

  • (vii)

    To verify successful recombination and loss of the pheS-gat or sacB-gat fragment, colonies can be patched onto MG ± 0.3% GS plates to confirm GS sensitivity. The same set of oligonucleotides used in step 12B(i) (Target-up-out and Target-down-out), which anneal outside of the homologous regions, should be used for PCR verification. PCR verification should be set-up exactly as described in steps 2–3 with extension time ~1 min/kb.

    ? TROUBLESHOOTING

Option B. Flp-mediated excision of the pheS-gat or sacB-gat fragment

  • (i)

    Inoculate the purified colony obtained in step 12B(ii) into 2 ml of LB and incubate at 37°C with shaking at 225 r.p.m. Once the OD600 reaches 0.8–1.5, harvest the cells by centrifuging at 16,000 g for 1 min. Discard the supernatant and resuspend the cell pellet in 20 μl of LB. Incubate the resuspended cells with DNA obtained in step 13B(iv) below immediately. ● TIMING ~8 h

  • (ii)

    Typically, set up four PCR reactions to obtain sufficient amounts of DNA. Multiply all of the following components by four and combine in a master mix. Pipet 50 μl of the master mix into four thin-walled PCR tubes. ● TIMING ~30 min

    Component Amount (μl) Final
    ddH2O 35.0 -
    10× Pfu buffer 5.0
    dNTPs (2 mM) 5.0 0.2 mM
    pCD13SK-Flp-oriT-asdEc (~20 ng μl−1) 1.0 ~20 ng
    Plac-up (30 μM) 1.0 30 pmol
    Flp-down (30 μM) 1.0 30 pmol
    Pfu polymerase (2.5 U μl−1) 2.0 5 U

    ▲ CRITICAL STEP It is essential to use Pfu polymerase or other polymerases that generate blunt-ends to avoid the addition of unwanted bases. The proofreading capability of Pfu polymerase will significantly increase the fidelity of the PCR products.

  • (iii)

    Carry out the PCR as below:

    Set the lid temperature to 98°C to prevent condensation of the sample during the reaction.

    Cycle Number Denaturation Annealing Extension Termination
    1 94°C, 2 min
    2–34 94°C, 30 s 58°C, 30 s 72°C, 3 min
    35 72°C, 5 min
    36 4°C, hold

    ■ PAUSE POINT At this time, the DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • (iv)

    Visualize PCR reactions via agarose gel electrophoresis using a 1.0% agarose gel submerged in TAE buffer (see REAGENT SETUP). A single PCR product of ~2.6 kb should be observed. Recover and purify DNA from the gel with desired kit/protocol and quantitate using a spectrophotometer. ● TIMING ~2.5 h

    ■ PAUSE POINT The DNA can be stored at 4°C for a short period of time. For extended storage, it is recommended that the reaction be placed in a −20°C freezer.

  • (v)

    Add 0.5–1.0 μg of PCR DNA (~10 μl) obtained in step 13B(iv) to the 20 μl resuspended cells from step 13B(i). Incubate the mixture for 30 min at room temperature without shaking. After 30 min, add 2 ml of LB and incubate at 37°C with shaking at 225 r.p.m. for 2 h. ● TIMING ~2.5 h

    ▲ CRITICAL STEP A small volume of the DNA sample (≤ 10 μl) should be added to the concentrated cells, as close contact between the cells and DNA is critical for efficient uptake of DNA. If the volume of the DNA sample exceeds 10 μl, dry it down in a vacuum concentrator.

  • (vi)

    Aliquot the recovery mix into two 1.5 ml microcentrifuge tube and centrifuge at 16,000 g for 1 min. Wash the pellet twice with 1 ml of 1× M9. Remove 800 μl of the 1× M9 and resuspend the cell pellet in the remainder of the 1× M9. Spread 50 μl and 150 μl of the cell suspension onto two MG plates containing 0.1% cPhe (B. pseudomallei with pKaKa2 and the pheS-gat cassette) or two LS + 15% sucrose plates (B. pseudomallei with pKaKa1 and the sacB-gat cassette). Colonies should be visible in ~2 d. ● TIMING ~2 d

  • (vii)

    To verify successful FRT recombination and loss of the pheS-gat or sacB-gat fragment, colonies can be patched onto MG ± 0.3% GS plates to confirm GS sensitivity. The same set of oligonucleotides as in step 12B(i) (Target-up-out and Target-down-out), which anneal outside of the homologous regions, should be used for PCR verification. PCR verification should be set-up exactly as described in steps 2–3 with extension time ~1 min/kb.

    ? TROUBLESHOOTING

(OPTIONAL) Curing of pKaKa1/pKaKa2 ● TIMING ~5 d

  • 14

    The pKaKa1/pKaKa2 helper plasmids can be cured from B. thailandensis or B. pseudomallei in one step. Option A describes the curing of pKaKa1 via pheS counter-selection and is achieved on cPhe containing media. Option B describes the curing of pKaKa2 via sacB counter-selection and is achieved on sucrose containing media.

Option A. Curing of pKaKa1 via pheS counter-selection ● TIMING ~5 d

  • (i)

    Pick 1–2 isolates of B. thailandensis or B. pseudomallei harboring pKaKa1 using a sterile inoculation loop and streak the cells out on MG + 0.1% cPhe plates. Incubate the plates at 37°C for 1–2 d until single colonies appear. ● TIMING ~2 d

  • (ii)

    To confirm the loss of pKaKa1 plasmid, patch 10–20 single colonies from MG + cPhe plate onto LB + Km500 (B. thailandensis) or Km1000 (B. pseudomallei) plate and incubate at 37°C. Be sure to include B. thailandensis or B. pseudomallei harboring pKaKa1 and wildtype B. thailandensis or B. pseudomallei on the plate as positive and negative controls, respectively. ● TIMING ~3 d

Option B. Curing of pKaKa2 via sacB counter-selection ● TIMING ~5 d

  • (i)

    Pick 1–2 isolates of B. pseudomallei harboring pKaKa2 using a sterile inoculation loop and streak the cells out on LS + 15% sucrose plates. Incubate the plates at 37°C for 1–2 d until single colonies appear. ● TIMING ~2 d

  • (ii)

    To confirm the loss of pKaKa2 plasmid, patch 10–20 single colonies from LS + sucrose plate onto MA plate and incubate at 37°C. Be sure to include B. pseudomallei harboring pKaKa2 and wildtype B. pseudomallei on the plate as positive and negative controls, respectively. ● TIMING ~3 d

? TROUBLESHOOTING

Troubleshooting advice can be found in Table 6.

TABLE 6.

Troubleshooting table.

STEPS PROBLEM POSSIBLE REASONS POSSIBLE SOLUTIONS
7 No second PCR product or high level of nonspecific products is obtained.
  1. High-GC fragment causes inefficient denaturation and non-specific annealing.

  2. Majority of the long primers is truncated (not PAGE purified) in this batch, resulting in first PCR products with truncated ends.

  3. Poor design of primers.

  1. Try a gradient PCR with annealing temperature range from 50–70°C, include 5–10% DMSO in the PCR reaction to aid amplification of high-GC fragments.

  2. Inform primer synthesis company and resynthezise the non-PAGE purified long primers free of charge (from IDT etc.), and retry the PCR.

  3. Redesign the primers so that their GC% is 50–60% with no significant primer-dimer and hairpin stracture formation, and the amplicons are as small as possible.

8A(iii)
8B(iii)
Arcing is observed when applying electopulse. Inefficient washing results in high salt concentration, or too much DNA is used. Perform additional washes to the cell pellet, and/or use reduced amount of DNA (e.g. 0.5–1 μg instead of 2 μg).
12(i)
13(vii)
No PCR product or high level of nonspecific products is obtained.
  1. High-GC fragment causes inefficient denaturation and non-specific annealing.

  2. Poor design of primers.

  3. The clones do not contain the desired KO or PO fragments.

  1. Try a gradient PCR with annealing temperature range from 50–70°C, include 5–10% DMSO in the PCR reaction to aid amplification of high-GC fragments.

  2. Redesign the primers so that their GC% is 50–60% with no significant primer-dimer and hairpin stracture formation, and the amplicons are as small as possible.

  3. Retry the recombineering.

12A(ii) No colonies are obtained Size of the PO fragments and toxicity of their gene products may be an issue. Use a fragment containing a low copy number origin for PO (e.g., pBBR-based origin).

● TIMING

  • Steps 1–7, preparing KO/PO DNA: 1 d

  • Step 8, introduction of pKaKa1/2: 3–4 d

  • Step 9, induction: 18 h

  • Steps 10–11, DNA incubation: 4 d

  • Step 12, PCR screening: 1–3 d

  • Step 13, recycling of markers: 3 d

  • Step 14, curing of pKaKa1/2: 5 d

ANTICIPATED RESULTS

Pull-out recombineering efficiency of chromosomal fragments from B. thailandensis

Utilizing the protocol provided will typically produce 40 to 200 colonies depending on the amount of DNA and type of PCR product used (Table 3). As an example, the B. thailandensis ara-operon was pulled-out of the chromosome with a PCR fragment containing a bhr origin of replication. Successful removal of the ara-operon was verified using an ara specific primer and a plasmid origin specific primer (Fig. 5a). High percentages (~90%) of the colonies contained the pulled-out fragment (Table 3 and Fig. 5a). Such percentages should be common as these numbers were obtained from experiments done in triplicate and bacteria that do not contain gat should not grow on media containing GS.

Pull-out recombineering in B. pseudomallei

Using the helper plasmid pKaKa2 (constructed with the ara-operon pulled-out from B. thailandensis), the efficiencies of pull-out recombineering in B. pseudomallei are shown in Table 4, which are relatively lower than pull-out in B. thailandensis (Table 3). Introduction of pKaKa2 into B. pseudomallei can be achieved through electroporation or conjugation. High efficiency can be expected from both methods. Selection and maintenance of pKaKa2 in B. pseudomallei is simple and tight, as cells without the plasmid will not be able to metabolize arabinose as a nutrient source. A higher concentration of glyphosate (0.3% instead of 0.04% for B. thailandensis) should be used for selection of the pull-out plasmid. Successful pull-out of chromosomal fragments should be confirmed by PCR using two oligos, where one anneals to the plasmid backbone and the other to the pull-out fragment (e.g., mba cluster in Fig. 5b). High frequencies (90–100%) of successful pull-out can be expected (Fig. 5b and Table 4). No GS resistant colonies were observed if the λ Red system was not induced, indicating recA-mediated recombination did not recombine 40–45 bp of homology at any detectable frequencies (Table 4).

Knock-out recombineering in B. pseudomallei strains

We first demonstrated the KO recombineering in B. pseudomallei by knocking out the mba cluster in strain 1026b. The efficiencies of knock-out recombineering in B. pseudomallei mba cluster are shown in Table 4, where 20–50 colonies are usually obtained when 0.5–2 μg KO DNA fragment is used. Independent GS resistant isolates were screened by phenotypic and PCR confirmation (Fig. 6a and 6b), with 100% frequency of successful knock-out. Generally, high frequencies (90–100%) are expected for the successful knock-out of chromosomal fragments, when the gat marker is used for selection (Fig. 6a and 6b). Two options, via a second λ Red mediated recombination or Flp-catalyzed excision, were provided for the removal of the pheS-gat or sacB-gat FRT-cassette from the mutant chromosomes. The λ Red mediated recombination results in a clean deletion of the chromosome fragment, whereas the Flp-catalyzed (λ Red independent) excision leaves a single “FRT-scar” inside the targeted fragment. Alternatively, instead of flp-containing PCR product incubation, we have expressed Flp transiently by conjugating the suicidal vector, pCD13SK-Flp-oriT-asdEc, from E. coli Δasd strain (E1354 in Table 1) and immediately counterselect the conjugation mix on cPhe- or sucrose-containing medium, which yielded GS sensitive clones. Use of the pheS-gat or sacB-gat FRT-cassette for knock-out makes the creation of unmarked mutations easy, as there is little to no resistance to cPhe or sucrose was observed. As an example, the removal of the pheS-gat cassette was close to 100% efficient (Fig. 6c and 6d with the mba cluster as an example). The confirmation of unmarked mutations is simple, as the PCR products amplified using outside primers are small (~200–500 bp; Fig. 6c and 6d). After introduction of the pKaKa2 plasmid, unmarked mutant could be obtained in approximately 10 d. pKaKa2 could be easily cured or maintained for the subsequent manipulation, such as creating multiple mutations in the same strain or introducing reporter gene fusions. If required, the curing of pKaKa2 on sucrose media could be confirmed by the inability to grow on arabinose as a sole carbon source. The curing efficiency was observed to be close to 100%. If pKaKa1 in conjunction with the sacB-gat fragment was used for B. pseudomallei KO, then the efficiencies for KO and curing of helper plasmid pKaKa1 are expected to be similar as when pKaKa2/pheS-gat is used. Since the first submission of this protocol, we have used this system to PO and KO genes in both species with relative ease.

Figure 6.

Figure 6

Phenotypic and PCR confirmation for the mba cluster knock-outs in the B. pseudomallei. As an example, the B. pseudomallei strain 1026b mba cluster was knocked-out, using the pheS-gat fragment with 45 bp homologous sequences to the mbaF and mbaS genes. Twenty five independent knock-out mutants were spotted onto CAS plate30, along with the wildtype 1026b strain (+) and the enterobactin negative E. coli mutant (−, JW0586-131) as the positive and negative control, respectively. Since the mba cluster is involved in malleobactin synthesis and secretion, knock-out mutants display the malleobactin-negative phenotype as an absence of orange-halo. The knockout frequency is 100% in these twenty five isolates. (b) Oligos annealing outside of the homologous region were used to screen ten isolates from (a) for successful KOs (oligos mbaF-out and mbaS-out as in Fig. 3). 100% (10 out of 10) of the GS resistant colonies were shown to have the pheS-gat fragment inserted into the mba-cluster, as indicated by the arrow. NC indicates negative control using wildtype 1026b as the PCR template. L indicates 1 kb DNA ladder from New England Biolabs. Following the second λ Red mediated recombination with overlapping oligos (c) or Flp-mediated excision (d), unmarked mutations were generated. PCR confirmation was done for both methods, using the same outside oligos as in (b), yielding smaller PCR products lacking pheS-gat as indicated by arrows in (c) and (d). In both (c) and (d), L indicates 100 bp DNA ladder from New England Biolabs. (e) After mutant construction, the pKaKa2 helper plasmid was cured from the 1026b-Δmba::pheS-gat via sacB counter-selection on sucrose-containing media. Total nucleic acids were purified from strain 1026b-Δmba::pheS-gat/pKaKa2 (lane 1) and four isolates of cured strain 1026b-Δmba::pheS-gat without pKaKa2 (lanes 2–5) for Southern hybridization analysis using the entire pKaKa2 plasmid as a probe. As indicated by arrow, the helper plasmid pKaKa2 only exists in strain 1026b-Δmba::pheS-gat/pKaKa2, while the entire pKaKa2 sequence is completely lost in 1026b-Δmba::pheS-gat after curing. L, pre-biotinylated DNA ladder from New England Biolabs (mixture of HindIII digested λ DNA and HaeIII digested φ 174 DNA). (f) To demonstrate the integrity of the PO fragment, boiling preps of two 1026b/pAM3G-mba isolates were electroporated directly into 1026b-mba::FRT mutant for the complementation study (B1 and B2). In addition, the same boiling preps of 1026b/pAM3G-mba were transformed into an E. coli restriction-minus strain, plasmids were then re-isolated from E. coli and reintroduced to complement the 1026b-mba::FRT mutant (E1 and E2). These four complemented strains were spotted on a CAS plate along with positive (+, wildtype 1026b) and negative (−, 1026b-mba::FRT) controls, and all four isolates regained the ability to produce malleobactin. (g) Boiling preps from five different isolates of 1026b/pAM3G-mba were electroporated into E. coli JW0586-1 strain, and the resulted strains were spotted onto CAS plates with positive (+, E. coli K-12 strain) and negative (−, E. coli JW0586-1 strain) controls. As shown, the B. pseudomallei 1026b mba-operon complemented the enterobactin-deficient phenotype of E. coli JW0586-1 strain.

To demonstrate and extend the use of λ red recombineering in other naturally transformable B. pseudomallei strains, we tested 20 additional B. pseudomallei strains and 9 were naturally transformable (Table 1). We chose these nine strains emcompassing clinical and environmental isolates (Table 1). The pheS-gat cassette was utilized to successfully KO the asd gene in these nine B. pseudomallei strains, and results are shown in Table 5 and Figure 7. The frequencies of true mutants were high (>50%, Table 5), even for KO of the essential asd gene9, and screening two colonies should yield muntants using this system.

Acknowledgments

This project was supported by Award Number AI065359 from the National Institute of Allergy and Infectious Diseases and by the Center of Biomedical Research Excellence grant P20RR018727 from the National Center for Research Resources of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official view of the funding agencies. We are grateful to Dr. H. P. Schweizer for the generous gift of constructs containing a modified sacB gene and the rhamnose inducible promoter.

Footnotes

AUTHOR CONTRIBUTION STATEMENTS

Y.K. created the constructs and performed the experiments in B. pseudomallei. M.H.N. performed the experiments in B. thailandensis. B.A.W. provided guidance for M.H.N in this project. A.T. and P.K. isolated and sequenced the B. pseudomallei clinical and environmental isolates on Table 1. T.T.H. designed and supervised the experiments. Y.K., M.H.N., and T.T.H. wrote this manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare that they have no competing financial interests.

References

  • 1.Sawitzke JA, et al. Recombineering: in vivo genetic engineering in E. coli, S. enterica, and beyond. Meth Enzymol. 2007;421:171–199. doi: 10.1016/S0076-6879(06)21015-2. [DOI] [PubMed] [Google Scholar]
  • 2.Zhang Y, Muyrers JPP, Testa G, Stewart AF. DNA cloning by homologous recombination in Escherichia coli. Nat Biotechnol. 2000;18:1314–1317. doi: 10.1038/82449. [DOI] [PubMed] [Google Scholar]
  • 3.Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA. 2000;97:6640–6645. doi: 10.1073/pnas.120163297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sun W, Wang S, Curtiss R., III Highly efficient methods for introducing successsive multiple scarless gene deletions and markerless gene insertions into the Yersinia pestis chromosome. Appl Environ Microbiol. 2008;74:4241–4245. doi: 10.1128/AEM.00940-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lesic B, Rahme LG. Use of the lambda Red recombinase system to rapidly generate mutants in Pseudomonas aeruginosa. BMC Mol Biol. 2008;9:20. doi: 10.1186/1471-2199-9-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insight into the pathogenicity of Burkholderia pseudomallei. Nature Rev Microbiol. 2006;4:272–282. doi: 10.1038/nrmicro1385. [DOI] [PubMed] [Google Scholar]
  • 7.Thongdee M, et al. Targetted mutagenesis of Burkholderia pseudomallei and Burkholderia thailandensis through natural transformation of PCR fragments. Appl Environ Microbiol. 2008;74:2985–2989. doi: 10.1128/AEM.00030-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Barrett AR, et al. Genetic tools for allelic replacement in Burkholderia species. Appl Environ Microbiol. 2008;74:4498–4508. doi: 10.1128/AEM.00531-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Norris MH, Kang Y, Lu D, Wilcox BA, Hoang TT. Glyphosate resistance as a novel select-agent-compliant, non-antibiotic selectable marker in chromosomal mutagenesis of the essential genes asd and dapB of Burkholderia pseudomallei. Appl Environ Microbiol. 2009;75:6062–6075. doi: 10.1128/AEM.00820-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Moore RA, et al. Contribution of gene loss to the pathogenic evolution of Burkholderia pseudomallei and Burkholderia mallei. Infect Immun. 2004;72:4172–4187. doi: 10.1128/IAI.72.7.4172-4187.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chandler JR, et al. Mutational analysis of Burkholderia thailandensis quorum sensing and self-aggregation. J Bacteriol. 2009;191:5901–9. doi: 10.1128/JB.00591-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Choi KH, Kumar A, Schweizer HP. A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for the DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Meth. 2006;64:391–397. doi: 10.1016/j.mimet.2005.06.001. [DOI] [PubMed] [Google Scholar]
  • 13.Mack K, Titball RW. Transformation of Burkholderia pseudomallei by Electroporation. Anal Biochem. 1996;242:73–76. doi: 10.1006/abio.1996.0430. [DOI] [PubMed] [Google Scholar]
  • 14.Lopez CM, Rholl DA, Trunck LA, Schweizer HP. Versatile Dual-Technology System for Markerless Allele Replacement in Burkholderia pseudomallei. Appl Environ Microbiol. 2009;75:6496–6503. doi: 10.1128/AEM.01669-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Choi KH, et al. Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol. 2008;74:1064–1075. doi: 10.1128/AEM.02430-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Antoine R, Locht C. Isolation and molecular characterization of a novel broad-host-range plasmid from Bordetella bronchiseptica with sequence similarities to plasmids from Gram-positive organisms. Mol Microbiol. 1991;6:1785–1799. doi: 10.1111/j.1365-2958.1992.tb01351.x. [DOI] [PubMed] [Google Scholar]
  • 17.Nakayama M, Ohara O. Improvement of recombination efficiency by mutation of Red proteins. BioTechniques. 2005;38:917–924. doi: 10.2144/05386RR02. [DOI] [PubMed] [Google Scholar]
  • 18.Alice AF, Lopez CS, Lowe CA, Ledesma MA, Crosa JH. Genetic and transcriptional analysis of the siderophore malleobactin biosynthesis and transport genes in the human pothogen Burkholderia pseudomallei K96243. J Bacteriol. 2006;188:1551–1566. doi: 10.1128/JB.188.4.1551-1566.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 2. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y: 2001. [Google Scholar]
  • 20.Wilson DE, Chosewood LC. Biosafety in microbiological and biomedical laboratories (BMBL) 5. Centers for Disease Control and Prevention; Atlanta, GA: 2007. [Google Scholar]
  • 21.Rholl DA, Trunck LA, Schweizer HP. Himar1 in vivo transposon mutagenesis of Burkholderia pseudomallei. Appl Environ Microbiol. 2008;74:7529–7535. doi: 10.1128/AEM.01973-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.DeShazer D, Brett PJ, Carlyon R, Woods DE. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutant and molecular characterization of the flagellin structural gene. J Bacteriol. 1997;179:2116–2125. doi: 10.1128/jb.179.7.2116-2125.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Brett PJ, DeShazer D, Woods DE. Burkholderia thailandensis sp nov., description of Burkholderia pseudomallei-like species. Int J Syst Bacteriol. 1998;48:317–320. doi: 10.1099/00207713-48-1-317. [DOI] [PubMed] [Google Scholar]
  • 24.Kang Y, Norris MH, Barrett AR, Wilcox BA, Hoang TT. Engineering of tellurite-resistant genetic tools for single-copy chromosomal analysis of Burkholderia spp. and characterization of the B thailandensis betBA-operon. Appl Environ Microbiol. 2009;75:4015–4027. doi: 10.1128/AEM.02733-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yanisch-Perron C, Vieira J, Messing J. Improved M13 cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene. 1985;33:103–119. doi: 10.1016/0378-1119(85)90120-9. [DOI] [PubMed] [Google Scholar]
  • 26.Kovach ME, et al. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different anitbiotic-resistance cassettes. Gene. 1995;166:175–176. doi: 10.1016/0378-1119(95)00584-1. [DOI] [PubMed] [Google Scholar]
  • 27.Schweizer HP, Klassen TR, Hoang T. Improved methods for gene analysis and expression in Pseudomonas. In: Nakazawa T, Furukawa K, Haas D, Silver S, editors. Molecular biology of Pseudomonads. American Society for Microbiology; Washington, D.C: 1996. pp. 229–237. [Google Scholar]
  • 28.Cardona ST, Valvano MA. An expression vector containing a rhamnose-inducible promoter provides tightly regulated gene expression in Burkholderia cenocepacia. Plasmid. 2005;54:219–228. doi: 10.1016/j.plasmid.2005.03.004. [DOI] [PubMed] [Google Scholar]
  • 29.Yu M, Tsang JSH. Use of ribosomal promoters from Burkholderia cenocepacia and Burkholderia cepacia for improved expression of transporter protein in Escherichia coli. Protein Expr Purif. 2006;49:219–227. doi: 10.1016/j.pep.2006.04.004. [DOI] [PubMed] [Google Scholar]
  • 30.Schwyn B, Neilands JB. Universal chemical assay for the detection and determination of siderophores. Analytical Biochemistry. 1987;160:47–56. doi: 10.1016/0003-2697(87)90612-9. [DOI] [PubMed] [Google Scholar]
  • 31.Baba T, et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006;2 doi: 10.1038/msb4100050. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES